Alexandra Gerlach, Content Producer

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.

Novel therapies and personalized treatment plans are improving outcomes for patients with ER-positive breast cancer.

Trastuzumab deruxtecan and trastuzumab emtansine address key challenges such as recurrence and metastases in HER2+ early breast cancer treatment.

At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs).

Experts highlight the importance of dosing and regimen optimization in breast cancer to improve treatment tolerability, reduce toxicities, and improve quality of life for patients.

Experts discuss advancements in hormone receptor–positive/HER2-negative breast cancer treatment while addressing safety, diversity, and fertility challenges.

Navtemadlin has demonstrated meaningful efficacy and safety as a monotherapy or combination treatment in various preclinical and clinical trials.

As experts in medication management and health education, pharmacists can work with the administration to promote effective strategies that reduce misinformation and improve public health outcomes.

Pelabresib is an investigational, oral, small molecule that inhibits bromodomain and extraterminal (BET) proteins.

The data support the use of supportive anemia care agents in combination with ruxolitinib (Jakafi; Incyte Corp).

Zenocutuzumab-zbco is a bispecific antibody that targets and binds to HER2 and HER3.

Metabolic bariatric surgery rates has decreased in response to increased use of glucagon-like peptide-1 (GLP-1) receptor agonists.

Anemia is a very common adverse effect associated with the use of ruxolitinib.

Postural orthostatic tachycardia syndrome (POTS) diagnoses have greatly increased following the COVID-19 pandemic.

E-cigarette manufacturers claim the products aid in smoking cessation for adults without the risk of adolescent usage.

The therapy has similar benefits for both older and younger patients with multiple myeloma.

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.

The addition of navitoclax was associated with durable response and potential disease modification.

Methemoglobinemia is a blood disorder that affects proper release of oxygen around the body.

The proposed rule would increase access to semaglutide for millions of Americans.

Acoramidis is a novel, highly potent transthyretin stabilizer.

Belantamab mafodotin demonstrated benefits in overall survival in the phase 3 DREAMM-7 trial.

Rusfertide may sustain hematocrit levels in patients with polycythemia vera.

Harpreet Bhatia, MD, MAS, FACC, discusses emerging new approaches to lipid lowering therapies.

Abelacimab is an investigational, selective, fully human monoclonal antibody.

Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.

Rachel Chandra, PharmD, MPH, FASHP shares methods for improving adherence to lipid lowering therapies discussed at the AHA 2024 Scientific Sessions.

Christian Ruff, MD, MPH shared the results of the AZALEA-TIMI 71 trial.

Leonard Egede, MD, MS, FACP discussed the association of historical redlining and contemporary structural racism on life expectancy.